Dual-targeted therapy with apremilast and vedolizumab in pyoderma gangrenosum associated with Crohn's disease
- 1 June 2020
- journal article
- letter
- Published by Wiley in The Journal of Dermatology
- Vol. 47 (6), E216-E217
- https://doi.org/10.1111/1346-8138.15283
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic ReviewJournal of Crohn's and Colitis, 2019
- Pyoderma gangrenosum: a review of pathogenesis and treatmentExpert Review of Clinical Immunology, 2018
- Skin Manifestations of Inflammatory Bowel DiseaseClinical Reviews in Allergy & Immunology, 2017
- Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosumJAAD Case Reports, 2017
- Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteriaInternational Journal of Dermatology, 2004